KLDO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
KLDO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Kaleido Biosciences's Enterprise Value is $-16.78 Mil. Kaleido Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 was $-87.45 Mil. Therefore, Kaleido Biosciences's EV-to-EBIT for today is 0.19.
The historical rank and industry rank for Kaleido Biosciences's EV-to-EBIT or its related term are showing as below:
During the past 6 years, the highest EV-to-EBIT of Kaleido Biosciences was 0.19. The lowest was 0.00. And the median was 0.00.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Kaleido Biosciences's Enterprise Value for the quarter that ended in Dec. 2021 was $85.02 Mil. Kaleido Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 was $-87.45 Mil. Kaleido Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 was -102.85%.
The historical data trend for Kaleido Biosciences's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaleido Biosciences Annual Data | |||||||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||
EV-to-EBIT | Get a 7-Day Free Trial | - | - | -1.18 | -3.84 | -0.97 |
Kaleido Biosciences Quarterly Data | |||||||||||||||||||
Dec16 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | |
EV-to-EBIT | Get a 7-Day Free Trial | -3.84 | -3.32 | -3.05 | -2.27 | -0.97 |
For the Biotechnology subindustry, Kaleido Biosciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Kaleido Biosciences's EV-to-EBIT falls into.
Kaleido Biosciences's EV-to-EBIT for today is calculated as:
EV-to-EBIT | = | Enterprise Value (Today) | / | EBIT (TTM) |
= | -16.776 | / | -87.45 | |
= | 0.19 |
Kaleido Biosciences's current Enterprise Value is $-16.78 Mil.
Kaleido Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kaleido Biosciences (OTCPK:KLDO) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.
Kaleido Biosciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2021 is calculated as:
Earnings Yield (Joel Greenblatt) % (Q: Dec. 2021 ) | = | EBIT | / | Enterprise Value (Q: Dec. 2021 ) |
= | -87.45 | / | 85.02444 | |
= | -102.85 % |
Kaleido Biosciences's Enterprise Value for the quarter that ended in Dec. 2021 was $85.02 Mil.
Kaleido Biosciences's EBIT for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-87.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Kaleido Biosciences's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Alison S Long | officer: Chief Medical Officer | KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421 |
Van Hylckama Vlieg Johan | officer: Chief Scientific Officer | C/O KALEIDO BIOSCIENCES, INC., 65 HAYDEN AVENUE, LEXINGTON MA 02421 |
Flagship Ventures Fund Iv, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Daniel L Menichella | director, officer: Chief Executive Officer | 79 TW ALEXANDER DRIVE, 4101 RESEARCH COMMONS, RESEARCH TRIANGLE PARK NC 27709 |
Kyriazi Theo Melas | director | 2150 ST. ELZEAR BLVD. WEST, LAVAL A8 H7L 4A8 |
Nutritional Health Ltp Fund General Partner Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Nutritional Health Ltp Fund, L.p. | 10 percent owner | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Anne Prener | director | C/O RUBIUS THERAPEUTICS, 399 BINNEY STREET SUITE 300, CAMBRIDGE MA 02139 |
William E. Duke | officer: CHIEF FINANCIAL OFFICER | C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807 |
Richard William Scalzo | officer: Principal Accounting Officer | 25 ALBERTA LANE, HOLLISTON MA 01746 |
Jean K Mixer | director | C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843 |
Jerald Korn | officer: General Counsel | 128 GORDON RD, NEWTON MA 02468 |
Flagship Ventures Fund V, L.p. | 10 percent owner | ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142 |
Michael W Bonney | director, officer: Executive Chair | 65 HAYDEN AVE, LEXINGTON MA 02421 |
Flagship Venturelabs V Manager Llc | 10 percent owner | 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142 |
From GuruFocus
By Marketwired Marketwired • 02-04-2021
By Marketwired Marketwired • 01-14-2021
By Marketwired Marketwired • 09-29-2021
By Marketwired Marketwired • 01-04-2021
By Marketwired Marketwired • 05-04-2021
By Marketwired Marketwired • 03-03-2021
By Marketwired Marketwired • 11-24-2020
By Marketwired Marketwired • 08-10-2021
By Marketwired Marketwired • 10-05-2021
By Marketwired Marketwired • 08-06-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.